Adipose derived Stem Cell
Phase 1Small molecule
Adipose derived Stem Cell is one of 60 small molecule programs targeting Stroke. It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
462 competitors in Stroke
#DrugCompanyPhaseTrials
1Folvite
Eli LillyPreclinical
Repatha
AmgenPreclinical
Pradaxa
Boehringer IngelheimPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Direct Anticoagulant
BayerPreclinical
Carbidopa-Levodopa
Neurocrine BiosciencesPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adipose derived Stem Cell. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity Hospital, Grenoble